G1 Therapeutics Inc (GTHX) Insider Sells $86,696.96 in Stock

G1 Therapeutics Inc (NASDAQ:GTHX) insider Rajesh Malik sold 3,776 shares of the firm’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $22.96, for a total value of $86,696.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

G1 Therapeutics Inc (NASDAQ:GTHX) traded down $0.33 during trading on Wednesday, reaching $22.71. The company had a trading volume of 75,900 shares, compared to its average volume of 85,540. The firm has a market capitalization of $643.72 and a price-to-earnings ratio of -10.56. G1 Therapeutics Inc has a 12-month low of $12.04 and a 12-month high of $28.67.

G1 Therapeutics (NASDAQ:GTHX) last posted its earnings results on Wednesday, November 8th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.01. research analysts predict that G1 Therapeutics Inc will post -2.72 EPS for the current year.

Institutional investors have recently bought and sold shares of the stock. Franklin Resources Inc. acquired a new stake in G1 Therapeutics in the second quarter valued at approximately $10,651,000. Laurion Capital Management LP acquired a new stake in G1 Therapeutics in the second quarter valued at approximately $3,488,000. Vanguard Group Inc. acquired a new stake in G1 Therapeutics in the second quarter valued at approximately $1,291,000. FMR LLC acquired a new stake in G1 Therapeutics in the second quarter valued at approximately $34,093,000. Finally, Goldman Sachs Group Inc. acquired a new stake in G1 Therapeutics in the second quarter valued at approximately $1,144,000. 43.25% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have recently issued reports on the company. Cowen restated a “buy” rating on shares of G1 Therapeutics in a research note on Wednesday, November 8th. BidaskClub upgraded G1 Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 3rd. BTIG Research assumed coverage on G1 Therapeutics in a research note on Tuesday, December 19th. They issued a “buy” rating and a $38.00 price objective for the company. Finally, Zacks Investment Research cut G1 Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $31.40.

ILLEGAL ACTIVITY NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2018/01/17/g1-therapeutics-inc-gthx-insider-sells-86696-96-in-stock.html.

About G1 Therapeutics

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Insider Buying and Selling by Quarter for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply